GPGary T. Pauly

Gary T. Pauly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gary T. Pauly has a total of 200 co-authors. Here are the top co-authors by number of shared publications:

  • Robert C. Moschel

    Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, PO Box B, Bldg. 538, Frederick, MD 21702, USA

    17 shared publications
  • Joel P. Schneider

    Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA

    9 shared publications
  • Albert M. Bobst

    Department of Chemistry, University of Cincinnati, Cincinnati, Ohio 45221, USA

    6 shared publications
  • Sreenivas Kanugula

    Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA

    6 shared publications
  • Anthony E. Pegg

    Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA

    5 shared publications
  • Natalia A. Loktionova

    Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, USA

    5 shared publications

Latest Publications

  • Open Access

    Id1 promotes clonal hematopoiesis in mice with Tet2 loss of function

    by Shweta Singh, Kristbjorn O. Gudmundsson, Tanmoy Sarkar, Brad L. Jakubison, Holly M. Morris, Sandra Burkett, Karim Baktiar, Gary T. Pauly, Dina M. Sigano, Joel P. Schneider, et al.

    Hematopoietic malignancies emerge through the acquisition of genetic mutations within hematopoietic stem and progenitor cells (HSPCs). Some mutations impart a selective growth advantage to HSPCs, which expand and contribute to mature blood cells. This expansion is termed clonal hematopoiesis (CH). Inhibitor of DNA binding 1 (ID1) protein is a transcriptional regulator of proliferation/differentiation of hematopoietic cells. HSPCs express low levels of Id1 that is induced by growth factors and other mediators of inflammatory during stress to promote HSPC expansion. Since chronic inflammation is associated with the progression of hematopoietic malignancies, reducing Id1 expression may reduce CH. Genetic ablation of Id1 in Tet2 −/− HSPCs reduces HSPC expansion/CH, extramedullary hematopoiesis, myeloid skewing, and genetic instability and delays the onset of disease. Mechanistically, p16 expression, senescence, and apoptosis were increased, and proliferation decreased in Tet2 −/− ;Id1 −/− HSPCs. Thus, ID1 may represent a therapeutic target to reduce CH and delay the onset of disease.


  • Open Access

    Anti-Fibrotic Potential of Tomentosenol A, a Constituent of Cerumen from the Australian Native Stingless Bee, Tetragonula carbonaria

    by Karina D. Hamilton, Daniel Czajkowski, Nicolas J. Kong, Trong D. Tran, Kirk R. Gustafson, Gary Pauly, Glen M. Boyle, Jacinta L. Simmons, Robert Steadman, Ryan Moseley, et al.

    Bioactivity-guided fractionation was used to isolate two compounds, tomentosenol A (1) and torellianone A (2), from a cerumen extract from Tetragonula carbonaria. The anti-fibrotic activity of these compounds was examined using human cultured neonatal foreskin fibroblasts (NFF) and immortalised keratinocytes (HaCaTs). Tomentosenol A (1), inhibited NFF and HaCaT cell proliferation and prevented NFF and HaCaT scratch wound repopulation at 12.5–25 µM concentrations. These inhibitory effects were associated with reduced cell viability, determined by tetrazolium dye (MTT) and sulforhodamine B (SRB) assays. Compound 1 further inhibited transforming growth factor-β1 (TGF-β1)-stimulated, NFF-myofibroblast differentiation and soluble collagen production; and was an effective scavenger of the model oxidant, 2,2-diphenyl-1-picrylhydrazyl (DPPH·), with an EC50 value of 44.7 ± 3.1 µM. These findings reveal significant anti-fibrotic potential for cerumen-derived tomentosenol A (1).


  • Open Access

    Structure‐based non‐nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants

    by Steven J. Smith, Gary T. Pauly, Katharine Hewlett, Joel P. Schneider, Stephen H. Hughes

    Non‐nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit reverse transcription and block the replication of HIV‐1. Currently, NNRTIs are usually used as part of a three‐drug combination given to patients as antiretroviral therapy. These combinations involve other classes of anti‐HIV‐1 drugs, commonly nucleoside reverse transcriptase inhibitors (NRTIs). However, attempts are being made to develop two‐drug maintenance therapies, some of which involve an NNRTI and an integrase strand transfer inhibitor. This has led to a renewed interest in developing novel NNRTIs, with a major emphasis on designing compounds that can effectively inhibit the known NNRTI resistant mutants. We have generated and tested novel rilpivirine (RPV) analogs. The new compounds were designed to exploit a small opening in the upper right periphery of the NNRTI binding pocket. The best of the new compounds, 12 , was a more potent inhibitor of the NNRTI‐resistant mutants we tested than either doravirine or efavirenz but was inferior to RPV. We describe the limitations on the modifications that can be appended to the “upper right side” of the RPV core and the effects of substituting other cores for the central pyrimidine core of RPV and make suggestions about how this information can be used in NNRTI design.


  • Open Access

    Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain

    by Jonathan D. Strope, Cody J. Peer, Tristan M. Sissung, O. Morgan Hall, Phoebe A. Huang, Emily M. Harris, Kirk R. Gustafson, Curtis J. Henrich, Dina M. Sigano, Gary T. Pauly, et al.

    Introduction: Transporters comprising the blood-brain barrier complicate delivery of many therapeutics to the central nervous system. The present study ascertained whether the natural product botryllamide G is viable for in vivo inhibition of ABCG2 using lapatinib as a probe for ABCB1 and ABCG2-mediated efflux from the brain. Methods: Wild-type and Mdr1a/Mdr1b (-/-) mice were treated with botryllamide G and lapatinib (“doublet therapy”), and while a separate cohort of wild-type mice was treated with botryllamide, tariquidar and lapatinib (“triplet therapy”). Results: Botryllamide G demonstrates biphasic elimination with a rapid distribution, decreasing below the in vitro IC50 of 6.9 µM within minutes, yet with a relatively slower terminal half-life (4.6 h). In Mdr1a/Mdr1b (-/-) mice, doublet therapy resulted in a significant increase in brain lapatinib AUC at 8 h (2058 h*ng/mL vs 4007 h*ng/mL; P = .031), but not plasma exposure (P = .15). No significant differences were observed after 24 h. Lapatinib brain exposure was greater through 1 h when wild-type mice were administered triplet therapy (298 h*pg/mg vs 120 h*pg/mg; P < .001), but the triplet decreased brain AUC through 24 h vs. mice administered lapatinib alone (2878 h*pg/mg vs 4461hr*ng/mL; P < .001) and did not alter the brain:plasma ratio. Conclusions: In summary, the ABCG2 inhibitor, botryllamide G, increases brain exposure to lapatinib in mice lacking Abcb1, although the combination of botryllamide G and tariquidar increases brain exposure in wild-type mice only briefly (1 h). Additional research is needed to find analogs of this compound that have better pharmacokinetics and pharmacodynamic effects on ABCG2 inhibition.


  • Open Access

    Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases

    by Brunilde Gril, Anurag N. Paranjape, Stephan Woditschka, Emily Hua, Emma L. Dolan, Jeffrey Hanson, Xiaolin Wu, Wojciech Kloc, Ewa Izycka-Swieszewska, Renata Duchnowska, et al.

    Brain metastases are devastating complications of cancer. The blood–brain barrier (BBB), which protects the normal brain, morphs into an inadequately characterized blood–tumor barrier (BTB) when brain metastases form, and is surrounded by a neuroinflammatory response. These structures contribute to poor therapeutic efficacy by limiting drug uptake. Here, we report that experimental breast cancer brain metastases of low- and high permeability to a dextran dye exhibit distinct microenvironmental gene expression patterns. Astrocytic sphingosine-1 phosphate receptor 3 (S1P3) is upregulated in the neuroinflammatory response of the highly permeable lesions, and is expressed in patients’ brain metastases. S1P3 inhibition functionally tightens the BTB in vitro and in vivo. S1P3 mediates its effects on BTB permeability through astrocytic secretion of IL-6 and CCL2, which relaxes endothelial cell adhesion. Tumor cell overexpression of S1P3 mimics this pathway, enhancing IL-6 and CCL-2 production and elevating BTB permeability. In conclusion, neuroinflammatory astrocytic S1P3 modulates BTB permeability.


  • Open Access

    Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations

    by Emilee Senkevitch, Wenqing Li, Julie A. Hixon, Caroline Andrews, Sarah D. Cramer, Gary T. Pauly, Timothy Back, Kelli Czarra, Scott K. Durum

    Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations


  • Open Access

    Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses

    by Eileen M. Geoghegan, Diana V. Pastrana, Rachel M. Schowalter, Upasana Ray, Wei Gao, Mitchell Ho, Gary T. Pauly, Dina M. Sigano, Campbell Kaynor, Ellen Cahir-McFarland, et al.


  • Open Access

    Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras

    by Julian C. Bahr, Robert W. Robey, Victoria Luchenko, Agnes Basseville, Arup R. Chakraborty, Hanna Kozlowski, Gary T. Pauly, Paresma Patel, Joel P. Schneider, Michael M. Gottesman, et al.

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Julian C. Bahr1, *, Robert W. Robey1, 2, *, Victoria Luchenko1, Agnes Basseville1, Arup R. Chakraborty1, Hanna Kozlowski2, Gary T. Pauly3, Paresma Patel3, Joel P. Schneider3, Michael M. Gottesman2, Susan E. Bates1, 4 1Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA 2Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA 3Chemical Biology Laboratory, National Cancer Institute, Frederick Cancer Research Center, Frederick, MD 21702, USA 4Columbia University Medical Center, Division of Hematology/Oncology, New York, NY 10032, USA *These authors contributed equally to this work Correspondence to: Susan E. Bates, email: seb2227@cumc.columbia.edu Keywords: romidepsin, Ras mutation, apoptosis, MEK inhibitor, AKT inhibitor Received: May 27, 2016 Accepted: September 01, 2016 Published: September 13, 2016


  • Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants

    by Steven J. Smith, Gary T. Pauly, Aamir Akram, Kevin Melody, Zandrea Ambrose, Joel P. Schneider, Stephen H. Hughes

    Background: Rilpivirine (RPV) is the latest non-nucleoside reverse transcriptase inhibitor (NNRTI) to be approved by Food and Drug Administration to combat HIV-1 infections. NNRTIs inhibit the chemical step in viral DNA synthesis by binding to an allosteric site located about 10 Å from the polymerase active site of reverse transcriptase (RT). Although NNRTIs potently inhibit the replication of wild-type HIV-1, the binding site is not conserved, and mutations arise in the binding pocket. Doravirine (DOR) is a new NNRTI in phase III clinical trials. Methods: Using a single round HIV-1 infection assay, we tested RPV and DOR against a broad panel of NNRTI-resistant mutants to determine their respective activities. We also used molecular modeling to determine if the susceptibility profile of each compound was related to how they bind RT. Results: Several mutants displayed decreased susceptibility to DOR. However, with the exception of E138K, our data suggest that the mutations that reduce the potency of DOR and RPV are non-overlapping. Thus, these 2 NNRTIs have the potential to be used together in combination therapy. We also show that the location at which DOR and RPV bind with the NNRTI binding pocket of RT correlates with the differences in their respective susceptibility to the panel of NNRTI-resistance mutations. Conclusions: This shows that (1) DOR is susceptible to a number of well-known NNRTI resistance mutations and (2) an understanding of the mutational susceptibilities and binding interactions of NNRTIs with RT could be used to develop pairs of compounds with non-overlapping mutational susceptibilities.